Does Glucagon-like Peptide-1 Ameliorate Oxidative Stress in Diabetes? Evidence Based on Experimental and Clinical Studies

Research output: Contribution to journal › Review › Research › peer-review

Standard

Does Glucagon-like Peptide-1 Ameliorate Oxidative Stress in Diabetes? Evidence Based on Experimental and Clinical Studies. / Petersen, Karen Ekkelund; Rakipovski, Günaj; Raun, Kirsten; Lykkesfeldt, Jens.

In: Current Diabetes Reviews, Vol. 12, No. 4, 2016, p. 331-358.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Petersen, KE, Rakipovski, G, Raun, K & Lykkesfeldt, J 2016, 'Does Glucagon-like Peptide-1 Ameliorate Oxidative Stress in Diabetes? Evidence Based on Experimental and Clinical Studies', Current Diabetes Reviews, vol. 12, no. 4, pp. 331-358. https://doi.org/10.2174/1573399812666150918150608

APA

Petersen, K. E., Rakipovski, G., Raun, K., & Lykkesfeldt, J. (2016). Does Glucagon-like Peptide-1 Ameliorate Oxidative Stress in Diabetes? Evidence Based on Experimental and Clinical Studies. Current Diabetes Reviews, 12(4), 331-358. https://doi.org/10.2174/1573399812666150918150608

Vancouver

Petersen KE, Rakipovski G, Raun K, Lykkesfeldt J. Does Glucagon-like Peptide-1 Ameliorate Oxidative Stress in Diabetes? Evidence Based on Experimental and Clinical Studies. Current Diabetes Reviews. 2016;12(4):331-358. https://doi.org/10.2174/1573399812666150918150608

Author

Petersen, Karen Ekkelund ; Rakipovski, Günaj ; Raun, Kirsten ; Lykkesfeldt, Jens. / Does Glucagon-like Peptide-1 Ameliorate Oxidative Stress in Diabetes? Evidence Based on Experimental and Clinical Studies. In: Current Diabetes Reviews. 2016 ; Vol. 12, No. 4. pp. 331-358.

Bibtex

@article{61ad58dfd4ad4c2c80ca975dcd204254,
title = "Does Glucagon-like Peptide-1 Ameliorate Oxidative Stress in Diabetes?: Evidence Based on Experimental and Clinical Studies",
abstract = "Glucagon-like peptide-1 (GLP-1) has shown to influence the oxidative stress status in a number of in vitro, in vivo and clinical studies. Well-known effects of GLP-1 including better glycemic control, decreased food intake, increased insulin release and increased insulin sensitivity may indirectly contribute to this phenomenon, but glucose-independent effects on ROS level, production and antioxidant capacity have been suggested to also play a role. The potential 'antioxidant' activity of GLP-1 along with other proposed glucose-independent modes of action related to ameliorating redox imbalance remains a controversial topic but could hold a therapeutic potential against micro- and macrovascular diabetic complications. This review discusses the presently available knowledge from experimental and clinical studies on the effects of GLP-1 on oxidative stress in diabetes and diabetes-related complications.",
keywords = "Animals, Diabetes Mellitus, Type 2, Drug Evaluation, Preclinical, Evidence-Based Practice, Glucagon-Like Peptide 1, Humans, Oxidative Stress, Peptides, Reactive Oxygen Species, Venoms, Journal Article, Review",
author = "Petersen, {Karen Ekkelund} and G{\"u}naj Rakipovski and Kirsten Raun and Jens Lykkesfeldt",
year = "2016",
doi = "10.2174/1573399812666150918150608",
language = "English",
volume = "12",
pages = "331--358",
journal = "Current Diabetes Reviews",
issn = "1573-3998",
publisher = "Bentham Science Publishers",
number = "4",

}

RIS

TY - JOUR

T1 - Does Glucagon-like Peptide-1 Ameliorate Oxidative Stress in Diabetes?

T2 - Evidence Based on Experimental and Clinical Studies

AU - Petersen, Karen Ekkelund

AU - Rakipovski, Günaj

AU - Raun, Kirsten

AU - Lykkesfeldt, Jens

PY - 2016

Y1 - 2016

N2 - Glucagon-like peptide-1 (GLP-1) has shown to influence the oxidative stress status in a number of in vitro, in vivo and clinical studies. Well-known effects of GLP-1 including better glycemic control, decreased food intake, increased insulin release and increased insulin sensitivity may indirectly contribute to this phenomenon, but glucose-independent effects on ROS level, production and antioxidant capacity have been suggested to also play a role. The potential 'antioxidant' activity of GLP-1 along with other proposed glucose-independent modes of action related to ameliorating redox imbalance remains a controversial topic but could hold a therapeutic potential against micro- and macrovascular diabetic complications. This review discusses the presently available knowledge from experimental and clinical studies on the effects of GLP-1 on oxidative stress in diabetes and diabetes-related complications.

AB - Glucagon-like peptide-1 (GLP-1) has shown to influence the oxidative stress status in a number of in vitro, in vivo and clinical studies. Well-known effects of GLP-1 including better glycemic control, decreased food intake, increased insulin release and increased insulin sensitivity may indirectly contribute to this phenomenon, but glucose-independent effects on ROS level, production and antioxidant capacity have been suggested to also play a role. The potential 'antioxidant' activity of GLP-1 along with other proposed glucose-independent modes of action related to ameliorating redox imbalance remains a controversial topic but could hold a therapeutic potential against micro- and macrovascular diabetic complications. This review discusses the presently available knowledge from experimental and clinical studies on the effects of GLP-1 on oxidative stress in diabetes and diabetes-related complications.

KW - Animals

KW - Diabetes Mellitus, Type 2

KW - Drug Evaluation, Preclinical

KW - Evidence-Based Practice

KW - Glucagon-Like Peptide 1

KW - Humans

KW - Oxidative Stress

KW - Peptides

KW - Reactive Oxygen Species

KW - Venoms

KW - Journal Article

KW - Review

U2 - 10.2174/1573399812666150918150608

DO - 10.2174/1573399812666150918150608

M3 - Review

C2 - 26381142

VL - 12

SP - 331

EP - 358

JO - Current Diabetes Reviews

JF - Current Diabetes Reviews

SN - 1573-3998

IS - 4

ER -

ID: 176919218